Research

Mixed

In non-beta tissues (liver, kidney, skeletal muscle, adipose), the mitochondrial benefits of GLP-1RAs are likely a combination of direct receptor signaling and indirect systemic improvements such as weight loss and reduced inflammation.

While GLP-1 drugs improve mitochondrial health in organs like the liver and muscles, these benefits are partly due to the overall reduction in body weight and blood sugar. It is a combined effect of losing weight and the drug's direct action on cells.

ModerateQualifiesMEDIUM confidence
In liver, kidney, and skeletal muscle, mitochondrial advantages are likely real but are more difficult to separate from secondary improvements in glycemia, adiposity, and systemic inflammation... Whether these are direct hepatocyte actions or mostly systemic effects is still unresolved.
Yosra Alhindi · Journal Of Advanced Pharmacy Education And Research · 2026

Why this rating

Evidence is mixed and difficult to disentangle in human studies compared to beta cells.

Source

Mitochondrial remodeling as a effector of glp-1 therapy in obesity and diabetes: review

Yosra Alhindi · Journal Of Advanced Pharmacy Education And Research · 2026

DOI 10.51847/bfye5lnqza

narrative_review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →